Yuanjie Niu

Disclosure information not submitted.

Presentation(s):

• MP59-19: Update of TRUCE-02: An Open Label, Single-arm, Phase 2 Study of Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma (HR-NMIBC) Which is Not Completely Resectable.

  Monday, May 16, 2022
  1:00 PM – 2:15 PM